[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100638551":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":17,"locations":22,"responsibleParty":40,"collaborators":10,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":10,"eligibilityCriteria":49,"healthyVolunteers":45,"sex":50,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":10,"studyType":56,"phases":10,"briefSummary":57,"conditions":58,"keywords":64,"overallStatus":25,"whyStopped":10,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"Qianfoshan Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"ABPA recurrence group and No ABPA recurrence group",null,"Patients with stable ABPA who visited multicenter hospitals between January 2021 and January 2025 were enrolled and followed up for one year. Based on the definition of ABPA relapse, they were categorized into a relapse group and a non-relapse group. Key features from medical records, inflammatory markers, fungal omics, radiomics, and pulmonary function tests were selected for model development.",[13],{"name":14,"affiliation":15,"role":16},"Qian Qi","Shandong First Medical University","STUDY_DIRECTOR",[18],{"name":14,"role":19,"phone":20,"phoneExt":10,"email":21},"CONTACT","+86 13706380314","qiqianqlh@163.com",[23],{"facility":24,"status":25,"city":26,"state":27,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"Department of Respiratory, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, #16766, Jingshi Road, Jinan City, Shandong Province, China, Jinan, Shandong 250014","RECRUITING","Jinan","Shandong","250014","China","CN",{"type":32,"coordinates":33},"Point",[34,35],116.99722,36.66833,{"lat":35,"lon":34},[38],{"name":39,"role":19,"phone":20,"phoneExt":10,"email":21},"Qian Qi, Dr.",{"type":41,"investigatorFullName":14,"investigatorTitle":42,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Prof","100638551","multi-omics-inflammatory-phenotype-for-abpa-recurrence-risk-prediction-100638551",false,"NCT07611838","Multi-Omics Inflammatory Phenotype for ABPA Recurrence Risk Prediction","Multi-Omics Data-Derived Inflammatory Phenotype for ABPA Recurrence Risk Prediction: A Multicenter Study","Inclusion Criteria:\n\n* Female and Male patients aged 18-80 years\n* diagnosis of Allergic Bronchopulmonary Aspergillosis ABPA accroding to the 2024 ISHAM Working Group Diagnostic Criteria\n\nExclusion Criteria:\n\n* Patients with malignant tumors or severe organ dysfunction (e.g., cardiac, cerebral, renal, etc.)\n* Patients with severe comorbidities, including active pulmonary tuberculosis, lung cancer, chronic heart failure (NYHA class Ⅳ), chronic kidney disease (CKD stage 5), decompensated cirrhosis, etc.\n* Patients with immunosuppressive status, such as HIV infection, long-term use of oral corticosteroids or immunosuppressive agents.\n* Pregnant or lactating women.\n* Patients with missing key data or incomplete medical records.","ALL","18 Years","80 Years",{"count":54,"type":55},300,"ESTIMATED","OBSERVATIONAL","To develop and externally validate a machine learning model for predicting the 1-year risk of relapse in patients with stable ABPA, and to further evaluate its value in risk stratification and clinical decision-making.",[59,60,61,62,63],"Allergic Bronchopulmonary Aspergillosis (ABPA)","Machine Learning","Multi-omics","Multicenter Study","Relapse",[65,63,60,62,61],"Allergic Bronchopulmonary Aspergillosis","2026-05-28",{"date":68,"type":69},"2026-06-01","ACTUAL",{"date":71,"type":69},"2021-01-01",{"date":73,"type":55},"2028-12-31",{"name":5,"class":6},1]